Skip to main content

Advertisement

Log in

Evaluation of Renal Function Testing in Older Australian Veterans Dispensed Medicines that Require Renal Function Monitoring

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Introduction

Renal function testing should be performed prior to initiating medicines that require dose adjustment in renal impairment, with ongoing monitoring in continued use, particularly in older people. There is little evidence regarding the extent to which renal function monitoring is performed in older Australians dispensed medicines requiring renal function monitoring.

Objective

The aim of this study was to determine the extent of renal function testing in older people dispensed medicines requiring renal function monitoring.

Methods

A retrospective analysis of administrative claims data from the Australian Government Department of Veterans’ Affairs was conducted for people aged 65 years or older who were dispensed one or more medicines requiring renal function monitoring, from 1 June 2019 to 30 September 2019, to investigate the proportion of people with a claim for a pathology test that included creatinine levels in the 6–12 months before or after dispensing of a medicine requiring renal function monitoring.

Results

There were 100,113 people who were dispensed at least one medicine requiring renal function monitoring during the study period, of whom 15% had a history of renal impairment and 16% had diabetes mellitus. Sixty-one percent had a claim for a test in the prior 6 months; this increased to 80% of participants with a claim for a test in the prior 12 months. The rate of claims for testing was lower in aged care facility residents compared with people living in the community (54% vs 62% in the previous 6 months; < 0.001), and was higher in people with diabetes (75% vs 58%; < 0.001), history of renal impairment (91% vs 59%; < 0.001) or heart failure (77% vs 60%; < 0.001) compared with those without these conditions.

Conclusion

Medicines that require renal function monitoring are commonly used in older Australians, and while the majority have claims for tests that include renal function, some are missing out.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Martin J, Sheaff M. Renal ageing. J Pathol. 2007;211(2):198–205.

    Article  CAS  Google Scholar 

  2. Davies E, O’mahony M. Adverse drug reactions in special populations–the elderly. Br J Clin Pharmacol. 2015;80(4):796–807.

    Article  CAS  Google Scholar 

  3. Helldén A, Bergman U, von Euler M, Hentschke M, Odar-Cederlöf I, Öhlén G. Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department. Drugs Aging. 2009;26(7):595–606.

    Article  Google Scholar 

  4. Cabré M, Elias L, Garcia M, Palomera E, Serra-Prat M. Avoidable hospitalizations due to adverse drug reactions in an acute geriatric unit. Analysis of 3,292 patients. Medicina Clínica (English Edition). 2018;150(6):209–14.

    Article  Google Scholar 

  5. Falconer N, Barras M, Cottrell N. Systematic review of predictive risk models for adverse drug events in hospitalized patients. Br J Clin Pharmacol. 2018;84(5):846–64.

    Article  Google Scholar 

  6. Kennedy DJ, Colyer WR, Brewster PS, Ankenbrandt M, Burket MW, Nemeth AS, et al. Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. Am J Kidney Dis. 2003;42(5):926–35.

    Article  Google Scholar 

  7. Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, et al. Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals. Drug Saf. 2017;40(7):597–606.

    Article  Google Scholar 

  8. Parameswaran Nair N, Chalmers L, Connolly M, Bereznicki BJ, Peterson GM, Curtain C, et al. Prediction of hospitalization due to adverse drug reactions in elderly community-dwelling patients (The PADR-EC Score). PLoS ONE. 2016;11(10):e0165757.

    Article  Google Scholar 

  9. Nair NP, Chalmers L, Bereznicki BJ, Curtain CM, Bereznicki LR. Repeat adverse drug reaction-related hospital admissions in elderly Australians: a retrospective study at the Royal Hobart Hospital. Drugs Aging. 2017;34(10):777–83.

    Article  Google Scholar 

  10. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt K-U, et al. Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122–37.

    Article  CAS  Google Scholar 

  11. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd. ; 2019.

  12. Saad R, Hallit S, Chahine B. Evaluation of renal drug dosing adjustment in chronic kidney disease patients at two university hospitals in Lebanon. Pharm Pract. 2019;17:1304.

    Google Scholar 

  13. Pillans P, Landsberg P, Fleming AM, Fanning M, Sturtevant J. Evaluation of dosage adjustment in patients with renal impairment. Intern Med J. 2003;33(1–2):10–3.

    Article  CAS  Google Scholar 

  14. Doody HK, Peterson GM, Watson D, Castelino RL. Retrospective evaluation of potentially inappropriate prescribing in hospitalized patients with renal impairment. Curr Med Res Opin. 2015;31(3):525–35.

    Article  Google Scholar 

  15. Schmidt-Mende K, Wettermark B, Andersen M, Elsevier M, Carrero JJ, Shemeikka T, et al. Prevalence of renally inappropriate medicines in older people with renal impairment—a cross-sectional register-based study in a large primary care population. Basic Clin Pharmacol Toxicol. 2019;124(3):256–65.

    Article  CAS  Google Scholar 

  16. Hanlon JT, Wang X, Handler SM, Weisbord S, Pugh MJ, Semla T, et al. Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patients. J Am Med Dir Assoc. 2011;12(5):377–83.

    Article  Google Scholar 

  17. Khanal A, Peterson GM, Castelino RL, Jose MD. Potentially inappropriate prescribing of renally cleared drugs in elderly patients in community and aged care settings. Drugs Aging. 2015;32(5):391–400.

    Article  Google Scholar 

  18. Castelino RL, Saunder T, Kitsos A, Peterson GM, Jose M, Wimmer B, et al. Quality use of medicines in patients with chronic kidney disease. BMC Nephrol. 2020;21(1):1–9.

    Article  Google Scholar 

  19. Teh XR, Lee SW. Pharmacists’ attitude, self-reported knowledge and practice of dosage adjustment among chronic kidney disease patients in Malaysia. J Pharm Pract Res. 2019;49(2):179–85.

    Article  Google Scholar 

  20. Kondo Y, Ishitsuka Y, Shigemori E, Irikura M, Kadowaki D, Hirata S, et al. Awareness and current implementation of drug dosage adjustment by pharmacists in patients with chronic kidney disease in Japan: a web-based survey. BMC Health Serv Res. 2014;14(1):615.

    Article  Google Scholar 

  21. Falconer N, Barras M, Cottrell N. How hospital pharmacists prioritise patients at high-risk for medication harm. Res Social Adm Pharm. 2019;15(10):1266–73.

    Article  Google Scholar 

  22. Australian Government Department of Veterans' Affairs D. Stats at a glance 2019 [cited 14 January 2019]. https://www.dva.gov.au/about-dva/statistics-about-veteran-population#ataglance.

  23. Australian Institute of Health and Welfare (AIHW). Health of veterans: Australian Government; 2020 [cited 01 July 2021]. https://www.aihw.gov.au/reports/australias-health/health-of-veterans.

  24. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2014. Oslo: WHO; 2013. http://www.whocc.no/filearchive/publications/2014_guidelines.pdf.

  25. Australian Government Department of Health. Schedule of Pharmaceutical Benefits: Commonwealth of Australia; 2020 [cited 2020 9 June 2020]. http://www.pbs.gov.au/browse/publications.

  26. Braunwald EJPiCD. Diabetes, heart failure, and renal dysfunction: the vicious circles. 2019;62(4):298-302.

  27. World Health Organization. International statistical classification of diseases and related health problems: 10th revision (ICD-10). http://www.who int/classifications/apps/icd/icd. 1992.

  28. Australian Government Department of Veterans' Affairs. Treatment Population Statistics. In: DEPARTMENT OF VETERANS' AFFAIRS TRANSPORT RADSSNR, editor. Canberra2019.

  29. Manski-Nankervis J-AE, Thuraisingam S, Sluggett JK, Lau P, Blackberry I, Ilomaki J, et al. Prescribing for people with type 2 diabetes and renal impairment in Australian general practice: a national cross sectional study. Prim Care Diabetes. 2019;13(2):113–21.

    Article  Google Scholar 

  30. Australian Government. Statistics and Insights: Australian Digital Health Agency; August 2020 [cited 2020 28 September].

  31. Leendertse AJ, van Dijk EA, De Smet PA, Egberts TC, van den Bemt PM. Contribution of renal impairment to potentially preventable medication-related hospital admissions. Ann Pharmacother. 2012;46(5):625–33.

    Article  Google Scholar 

  32. Chaplin S. Chronic heart failure in adults: diagnosis and management. Prescriber. 2019;30(1):16–8.

    Article  Google Scholar 

  33. Bell J, Blacker N, LeBlanc V, Alderman CP, Phillips A, Rowett D, et al. Medications: prescribing for older people with chronic renal impairment. Aust Fam Phys. 2013;42(1/2):24.

    Google Scholar 

  34. Ganesan K, Rana MBM, Sultan S. Oral Hypoglycemic Medications. StatPearls. Treasure Island (FL): StatPearls Publishing, Copyright © 2020, StatPearls Publishing LLC.; 2020.

  35. Health' AGDo. Pathology Questions and Answers 27 February 2019 [cited 28 September]. https://www1.health.gov.au/internet/main/publishing.nsf/Content/pathqa#coning.

  36. Australian Institute of Health and Welfare (AIHW). Healthcare usage and costs. A comparison of veterans and war widows and widowers with the rest of the community. Cat. no. PHE 42 ed. Canberra: AIHW; 2002.

Download references

Acknowledgements

This research was funded by the Australian Government Department of Veterans’ Affairs as part of the delivery of the Veterans’ MATES programme.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gizat M. Kassie.

Ethics declarations

Funding

There was no funding received to conduct this particular study.

Conflict of Interest

Lisa M. Kalisch Ellett, Gizat M. Kassie, Emmae N. Ramsay, Nicole L. Pratt and Elizabeth E. Roughead declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Ethical Approval

Ethics approval was obtained from the University of South Australia, and the Departments of Defence and Veterans’ Affairs Human Research Ethics Committees.

Author Contributions

LMKE—study design, data analysis and interpretation, drafting of the manuscript. GMK—study design, data interpretation, writing the manuscript, critical revision of the manuscript for important intellectual content. ENR, NLP, EER—study design, data interpretation, critical revision of the manuscript for important intellectual content. All authors read and approved the final version.

Availability of data and material

Unpublished data related to this study can be requested from the corresponding author Dr Gizat Molla Kassie by email (gizat.kassie@unisa.edu.au).

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 36 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalisch Ellett, .M., Kassie, .M., Ramsay, E.N. et al. Evaluation of Renal Function Testing in Older Australian Veterans Dispensed Medicines that Require Renal Function Monitoring. Drugs Aging 38, 995–1002 (2021). https://doi.org/10.1007/s40266-021-00892-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-021-00892-0

Navigation